Answers are grounded in this paper and cite their sources.
Dementia is the final stage of a neurodegenerative disease characterized by progressive loss of cognitive and daily living skills. The pathological process is associated with the aging process, affecting up to 66% of individuals older than 65. The initial symptoms, which may include memory loss, behavioral alterations, and neuropsychiatric conditions, should be taken seriously by healthcare professionals. It is important to recognize that patients may exhibit these impairments long before the onset of dementia. The primary objective of treatment should be to delay the progression of the disease, as opposed to merely managing symptoms. While pharmacological interventions, including acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, have demonstrated efficacy in the management of cognitive decline, their utilization is constrained by adverse effects and poor long-term tolerability. A substantial body of evidence suggests that the standardized Ginkgo biloba leaf extract EGb 761 ® may offer a promising alternative. It has been demonstrated to contribute to the symptomatic treatment of age-related cognitive impairment and dementia. In India, Tebokan ® with EGb 761 ® as its active ingredient, is the sole phytopharmaceutical that has been approved for the treatment of brain disorders, including reduced intellectual capacity and alertness, and memory problems. It is recommended as part of a holistic treatment approach, which also addresses the risk factors for dementia, such as hearing loss, hypertension, excessive alcohol consumption, obesity, smoking, depression, loneliness, physical inactivity, and diabetes. Due to its favorable tolerability and safety profile, Tebokan ® is a suitable treatment option for patients in the early stages of the disease.
No takes yet. Share an insight, caveat, or question.
Shukla et al. (2026) studied this question.